With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.
Corsera Health, Inc., leading the future of cardiovascular health through prediction and prevention, today announced the filing of a clinical trial notification (CTN) to initiate a Phase 1 clinical ...
CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation. EINPresswire/ -- CRISPR Gene Editing: A Technological Overview CRISPR gene editing has ...
Welltica+ on MSN
Study reveals a new, gentle method to lower bad cholesterol
A new DNA-based therapy could cut cholesterol nearly in half—without relying on statins or causing side effects.
GB News on MSN
Cholesterol treatment cut levels by 47% - offering hope to millions who can't tolerate statins
Scientists have developed a breakthrough therapy that could revolutionise the treatment of high cholesterol, which currently ...
From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.
Ms. Harris is a 63-year-old woman with a recent MI and dyslipidemia who has complaints with her statin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback